Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




C - Reactive Protein Measurement Aids Assessment of Bowel Disease

By LabMedica International staff writers
Posted on 03 Aug 2010
The level of C-reactive protein in the blood is used to assess disease activity in diverse inflammatory disorders including inflammatory bowel disease (IBD).

High-sensitivity CRP (hs-CRP) measures CRP levels that were previously thought to be under the detection limit. More...
In pediatric IBD, this kind of highly sensitive marker is needed for the detection of the presence of inflammation.

Inflammatory bowel disease is a chronic, relapsing, and remitting disease of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. CRP is an acute phase protein produced by liver that is used in the diagnosis of inflammatory disorders. Serum hs-CRP can be analyzed using enzyme linked immunoassays (ELISA) kits. A team from Finland investigated the association between hs-CRP and clinical and histological activity in pediatric IBD patients, and evaluated the effect of glucocorticoid treatment on the hs-CRP levels.

The serum samples from 39 Finnish children with IBD were analyzed using a human C-reactive protein Instant ELISA kit (Bender MedSystems GmbH, Vienna, Austria; www.bendermedsystems.com). A further 22 children with IBD and followed for acute response to glucocorticoids, and 33 pediatric non-IBD patient were also tested. The hs-CRP Instant ELISA kit has an intra-assay coefficient of variation (C.V.) of 6.9%, and an interassay C.V. of 13.1% and detection limit of 3 × 10-6 mg/L.

The study, carried out at the University of Helsinki (Helsinki, Finland), showed that standard CRP test is negative in a considerable number of pediatric patients with active IBD and the routine measurement of CRP is thus not informative enough. The hs-CRP test detects low levels of CRP, but disappointingly, it does not help to distinguish children with active intestinal inflammation from those with quiescent disease or those responding to glucocorticoid treatment from nonresponders. Interestingly, the levels of hs-CRP correlated with the presence of ileal inflammation.

This study reinforces the concept that a significant number of pediatric patients with active IBD may present with CRP levels that are under the detection limit. Here, standard CRP was under the detection limit of 5 mg/L in 60% of the young patients with active colitis. All patients with undetectable standard CRP had measurable hs-CRP levels, but there was no cut-off value for low CRP values with which to differentiate active and dormant disease. The results of the clinical investigation were published on June 21, 2010, in the World Journal of Gastroenterology.

Related Links:

Bender MedSystems GmbH
University of Helsinki





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.